BIIB•benzinga•
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Summary
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga